Interactions between tumor cells and microenvironment in breast cancer: A new opportunity for targeted therapy

Cancer Science

Volumn 103, Issue 3, 2012, Pages 400-407

  Mitra, Shreya ^a   Stemke Hale, Katherine ^a   Mills, Gordon B ^a   Claerhout, Sofie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; METFORMIN; TAMOXIFEN; TUMOR MARKER; ANTINEOPLASTIC AGENT;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL INTERACTION; DRUG MECHANISM; DRUG UPTAKE; HUMAN; MAMMARY GLAND; METABOLIC PARAMETERS; MOLECULARLY TARGETED THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; FEMALE; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; METFORMIN; TUMOR MICROENVIRONMENT;

EID: 84859711066     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02183.x     Document Type: Review

References (76)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002; 296: 1046-9.
3. Haslam SZ, Woodward TL. Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Res 2003; 5: 208-15.
4. Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med 2009; 15: 842-4.
5. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
6. Tiede B, Kang Y. From milk to malignancy: The role of mammary stem cells in development, pregnancy and breast cancer. Cell Res 2011; 21: 245-57.
7. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
8. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target.? Nat Rev Cancer 2010; 10: 871-7.
9. Radisky ES, Radisky DC. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 2007; 8: 279-87.
10. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation Cell Metab 2008; 7: 11-20.
11. Holliday C, Rummel S, Hooke JA et al. Genomic instability in the breast microenvironment.? A critical evaluation of the evidence. Expert Rev Mol Diagn 2009; 9: 667-78.
12. Trimboli AJ, Cantemir-Stone CZ, Li F et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009; 461: 1084-91.
13. Houghton J, Li H, Fan X et al. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev 2010; 19: 1153-66.
14. Guppy M, Leedman P, Zu X, Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J 2002; 364: 309-15.
15. Possemato R, Marks KM, Shaul YD et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476: 346-50.
16. Palaskas N, Larson SM, Schultz N et al. 18F-fluorodeoxy-glucose positron emission tomography marks Myc-overexpressing human basal-like breast cancers. Cancer Res 2011; 71: 5164-74.
17. Subik K, Lee J-F, Baxter L et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer 2010; 4: 35-41.
18. Macdonald RG, Byrd JC. The insulin-like growth factor II/mannose 6- phosphate receptor: implications for IGF action in breast cancer. Breast Dis 2003; 17: 61-72.
19. Stemke-Hale K, Gonzalez-Angulo A, Lluch A et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-91.
20. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the role of PI3K/AKT/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010; 10(Suppl 3): S59-65.
21. Koda M, Kanczuga-Koda L, Sulkowska M, Surmacz E, Sulkowski S. Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy. BMC Cancer 2010; 10: 320-8.
22. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
23. Schafer ZT, Grassian AR, Song L et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009; 461: 109-13.
24. Sonveaux P, Vegran F, Schroeder T et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008; 118: 3930-42.
25. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66: 5977-80.
26. Gao P, Tchernyshyov I, Chang T et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-5.
27. Solaini G, Baracca A, Lenaz G, Sgarbi G. Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta 2010; 1797: 1171-7.
28. Christofk HR, Vander Heiden MG, Harris MH et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-3.
29. Lüftner D, Mesterharm J, Akrivakis C et al. Tumor type m2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20: 5077-82.
30. Benesch C, Schneider C, Voelker H-U et al. The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAKT expression in breast cancer. Anticancer Res 2010; 30: 1689-94.
31. Polyak K, Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2010; 2: a003244.
32. Denko NC. Hypoxia, HIF-1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-13.
33. Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006; 66: 6699-707.
34. Generali D, Buffa FM, Berruti A et al. Phosphorylated ER-a, HIF-1a, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 2009; 27: 227-34.
35. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-34.
36. Dales J-P, Beaufils N, Silvy M et al. Hypoxia inducible factor 1 alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer. BMC Med 2010; 8: 44.
37. Stuelten CH, Busch JI, Tang B et al. Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-b mediated mechanism in a mouse xenograft model of breast cancer. PLoS ONE 2010; 5: e9832.
38. Goetz JG, Minguet S, Navarro-Lérida I et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011; 146: 148-63.
39. Martin FT, Dwyer RM, Kelly J et al. Potential role of mesenchymal stem cells (MSCS) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 2010; 124: 317-26.
40. Végran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-jB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 2011; 71: 2550-80.
41. Kojima Y, Acar A, Eaton E et al. Autocrine TGF-b and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010; 107: 20009-14.
42. Pavlides S, Whitaker-Menezes D, Castello-Cros R et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009; 8: 3984-4001.
43. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010; 9: 3256-76.
44. Gonzalez-Angulo A, Ferrer-Lozano J, Stemke-Hale K et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 2011; 10: 1093-101.
45. Dupont Jensen J, Laenkholm A-V, Knoop A et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 2011; 17: 667-77.
46. Ding L, Ellis M, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
47. Navin N, Kendall J, Troge J et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-4.
48. Pinheiro C, Albergaria A, Paredes J et al. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 2010; 56: 860-7.
49. Hu M, Yao J, Cai L et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005; 37: 899-906.
50. Tan E, Yan M, Campo L et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 2009; 100: 405-11.
51. Andre F, Berrada N, Desmedt C. Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. Curr Opin Oncol 2010; 22: 547-51.
52. Witkiewicz AK, Dasgupta A, Sotgia F et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174: 2023-34.
53. Sloan EK, Ciocca DR, Pouliot N et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009; 174: 2035-43.
54. Savage K, Lambros MBK, Robertson D et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007; 13: 90-101.
55. Mercier I, Bryant KG, Sotgia F et al. Using caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the caveolin-1 (p132l) mutation. Cell Cycle 2009; 8: 1396-401.
56. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R et al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 2010; 9: 1960-71.
57. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012; 7: DOI: 10.1146/annurev-pathol-011811-120856 [Epub ahead of print].
58. Lafkas D, Trimis G, Papavassiliou AG, Kiaris H. p53 mutations in stromal fibroblasts sensitize tumors against chemotherapy. Int J Cancer 2008; 123: 967-71.
59. Barkan D, Green J, Chambers A. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 2010; 46: 1181-8.
60. Naumov G, Bender E, Zurakowski D et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006; 98: 316-25.
61. Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa C et al. Geneexpression profiles, tumor microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated approach. Cancer Treat Rev 2010; 36: 477-84.
62. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. Curr Mol Med 2010; 10: 674-91.
63. Gonzalez-Angulo A, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010; 16: 1695-700.
64. Bodmer M, Meier C, Krähenbühl S, Jick S, Meier C. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33: 1304-8.
65. Kruse JA. Metformin-associated lactic acidosis. J Emerg Med 2001; 20: 267-72.
66. Guppy A, Jamal-Hanjani M, Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 2011; 7: 727-36.
67. Foretz M, Hébrard S, Leclerc J et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010; 120: 2355-69.
68. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-73.
69. Deng XS, Wang S, Deng A, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012; (in press).
70. Liu B, Fan Z, Edgerton SM et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8: 2031-40.
71. Planche A, Bacac M, Provero P et al. Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS ONE 2011; 6: e18640.
72. Hill JJ, Tremblay T-L, Pen A et al. Identification of vascular breast tumor markers by laser capture microdissection and label-free LC-MS. J Proteome Res 2011; 10: 2479-93.
73. Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-27.
74. Nakamura T, Kuwai T, Kim J et al. Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia 2007; 9: 979-86.
75. Camp J, Elloumi F, Roman-Perez E et al. Interactions with fibroblasts are distinct in basal-like and luminal breast cancers. Mol Cancer Res 2011; 9: 3-13.
76. Tang F, Barbacioru C, Wang Y et al. mRNA seq whole-transcriptome analysis of a single cell. Nat Method 2009; 6: 377-82.